JP7663503B2 - アゼチジニルｏ－糖タンパク質－２－アセトアミド－２－デオキシ－３－ｄ－グルコピラノシダーゼ阻害剤 - Google Patents

アゼチジニルｏ－糖タンパク質－２－アセトアミド－２－デオキシ－３－ｄ－グルコピラノシダーゼ阻害剤 Download PDF

Info

Publication number
JP7663503B2
JP7663503B2 JP2021552999A JP2021552999A JP7663503B2 JP 7663503 B2 JP7663503 B2 JP 7663503B2 JP 2021552999 A JP2021552999 A JP 2021552999A JP 2021552999 A JP2021552999 A JP 2021552999A JP 7663503 B2 JP7663503 B2 JP 7663503B2
Authority
JP
Japan
Prior art keywords
disease
optionally substituted
compound
pharma
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021552999A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022524077A5 (https=
JPWO2020185593A5 (https=
JP2022524077A (ja
Inventor
ジェナング，ネイサン
ガッキアン，ケビン・エム
ベッセルズ，ジェフリー
ジャーン，レイ
ジアナタッシオ，ライアン
リン，エドワード・イン・シアン
シン，ジリ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Publication of JP2022524077A publication Critical patent/JP2022524077A/ja
Publication of JP2022524077A5 publication Critical patent/JP2022524077A5/ja
Publication of JPWO2020185593A5 publication Critical patent/JPWO2020185593A5/ja
Application granted granted Critical
Publication of JP7663503B2 publication Critical patent/JP7663503B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2021552999A 2019-03-08 2020-03-06 アゼチジニルｏ－糖タンパク質－２－アセトアミド－２－デオキシ－３－ｄ－グルコピラノシダーゼ阻害剤 Active JP7663503B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962815553P 2019-03-08 2019-03-08
US62/815,553 2019-03-08
PCT/US2020/021479 WO2020185593A1 (en) 2019-03-08 2020-03-06 Azetidinyl 0-glyc0pr0tein-2-acetamid0-2-deoxy-3-d-gluc0pyran0sidase inhibitors

Publications (4)

Publication Number Publication Date
JP2022524077A JP2022524077A (ja) 2022-04-27
JP2022524077A5 JP2022524077A5 (https=) 2023-03-14
JPWO2020185593A5 JPWO2020185593A5 (https=) 2023-03-14
JP7663503B2 true JP7663503B2 (ja) 2025-04-16

Family

ID=69960768

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021552999A Active JP7663503B2 (ja) 2019-03-08 2020-03-06 アゼチジニルｏ－糖タンパク質－２－アセトアミド－２－デオキシ－３－ｄ－グルコピラノシダーゼ阻害剤

Country Status (5)

Country Link
US (1) US12421224B2 (https=)
EP (1) EP3935055A1 (https=)
JP (1) JP7663503B2 (https=)
MA (1) MA55203A (https=)
WO (1) WO2020185593A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121405694A (zh) * 2024-07-26 2026-01-27 浙江同源康医药股份有限公司 Oga抑制剂及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016517411A (ja) 2013-03-14 2016-06-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ グリコシダーゼ阻害剤
WO2018109202A1 (en) 2016-12-16 2018-06-21 Janssen Pharmaceutica Nv Monocyclic oga inhibitor compounds
WO2018154133A1 (en) 2017-02-27 2018-08-30 Janssen Pharmaceutica Nv [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as oga inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
EP2780013A4 (en) 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
EP2780014A4 (en) 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
WO2013078320A1 (en) 2011-11-21 2013-05-30 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
NZ628762A (en) 2012-02-10 2016-07-29 Constellation Pharmaceuticals Inc Modulators of methyl modifying enzymes, compositions and uses thereof
SI2953941T1 (sl) 2013-02-11 2017-08-31 Constellation Pharmaceuticals, Inc. Modulatorji metil-modificirajočih encimov, sestavki in uporabe le-teh
WO2014151142A1 (en) 2013-03-15 2014-09-25 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP3033334A1 (en) 2013-08-15 2016-06-22 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016517411A (ja) 2013-03-14 2016-06-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ グリコシダーゼ阻害剤
WO2018109202A1 (en) 2016-12-16 2018-06-21 Janssen Pharmaceutica Nv Monocyclic oga inhibitor compounds
WO2018154133A1 (en) 2017-02-27 2018-08-30 Janssen Pharmaceutica Nv [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as oga inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
C.G.WERMUTH編，『最新 創薬化学 上巻』，株式会社テクノミック，1998年08月15日，235-271頁，13章 等価置換に基づく分子の変換
野崎正勝 等，創薬化学，第１版，株式会社化学同人，1995年，p.98-99

Also Published As

Publication number Publication date
MA55203A (fr) 2022-01-12
WO2020185593A1 (en) 2020-09-17
EP3935055A1 (en) 2022-01-12
US12421224B2 (en) 2025-09-23
JP2022524077A (ja) 2022-04-27
US20220259197A1 (en) 2022-08-18

Similar Documents

Publication Publication Date Title
JP7044769B2 (ja) Ｕｓｐ３０の阻害剤としての活性を有するシアノ置換複素環
CN113072542B (zh) RORγt抑制剂及其制备方法和用途
JP7577655B2 (ja) 環状尿素
CA3050625C (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors
AU2019234759B2 (en) O-glycoprotein-2-acetamido-2-deoxy-3-D-glycopyranosidase inhibitors
WO2016147659A1 (en) Bicyclic imidazolo derivative
US20230025807A1 (en) Cd38 inhibitors
US11414395B2 (en) Heterocyclic compounds as modulators of mGluR7
MX2014004254A (es) Derivados de carbamato / urea que contienen anillos de piperidina y piperazina como inhibidores del receptor h3.
KR20160098500A (ko) 플루오로-나프틸 유도체
TW202130643A (zh) 螺環o-醣蛋白-2-乙醯胺基-2-去氧-3-d-葡萄哌喃糖苷酶抑制劑
JP7663503B2 (ja) アゼチジニルｏ－糖タンパク質－２－アセトアミド－２－デオキシ－３－ｄ－グルコピラノシダーゼ阻害剤
EP3891146B1 (en) Morpholinyl, piperazinyl, oxazepanyl and diazepanyl derivatives useful as o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
CN109988170A (zh) 八氢吡咯并[3,4-c]吡咯衍生物及其用途
EP4126849A1 (en) N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as sstr4 agonists
US11459324B2 (en) O-glycoprotein-2-acetamido-2-deoxy-3-D-glycopyranosidase inhibitors
CN109988169A (zh) 八氢吡咯并[3,4-c]吡咯衍生物及其用途
CN109734712B (zh) 芳基或杂芳基取代的吡咯烷酰胺衍生物及其用途
CN109956945B (zh) 八氢吡咯并[3,4-c]吡咯衍生物及其用途
HK40046057B (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors
HK40046057A (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors
CA3256816A1 (en) LRRK2 INHIBITORS

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230306

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230306

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240613

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241209

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20241226

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250306

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250404

R150 Certificate of patent or registration of utility model

Ref document number: 7663503

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150